[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-loss":691},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,43,65,83,112,138,158,208,229,254,277,300,357,393,424,446,466,513,533,555,584,606,628,653,674],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053740",false,"NCT07700030","High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)","Inclusion Criteria:\n\n* Age 30- 60 years\n* BMI 27.0-37.0 kg\u002Fm² at screening\n* English speaking (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n* Received a prescription for tirzepatide, a second-generation oral or injectable dual GIP\u002FGLP-1 receptor agonist (Zepbound\u002FMounjaro) that is FDA-approved for obesity; and\n\n  * Has not yet started tirzepatide and agrees to complete a 4-week run-in period at the initial dose with \\\u003C3% weight loss from baseline; OR\n  * Has initiated tirzepatide and is within the first 4 weeks at the initial dose with \\\u003C3% weight loss from pre-treatment baseline.\n* On a stable regimen for major chronic conditions (e.g., antihypertensives, lipid-lowering agents, oral antidiabetics, hypothyroidism) for ≥ 8 weeks prior to enrollment.\n* Willing and able to:\n\n  * (i) Receive high-protein diet counseling and attempt to achieve \\~2.5 g\u002Fkg FFM \u002Fday protein;\n  * (ii) Attend scheduled nutrition telehealth visits with an RDN;\n  * (iii) Medically cleared for moderate-intensity resistance training 2 days\u002Fweek (no condition that would preclude safe participation in either diet-only or diet plus resistance training).\n* Willing and able to undergo whole-body MRI at baseline and 6 months without sedation.\n* Able to understand procedures and provide written informed consent in English (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n\nExclusion Criteria:\n\n* Patients currently prescribed oral or injectable incretin mimetics containing GLP-1RAs, including Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide. Participants who are currently prescribed tirzepatide and have been using for \\>4 weeks will also be excluded.\n* Prior use of incretin mimetics containing GLP-1RAs with \\>3% weight loss in a 4-week period\n* Lost \\>5% body weight in the past 6 months\n* Has consistently resistance trained (\\>10 sessions) in the last year\n* Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months\n* Participants who live outside of the tri-state area and\u002For are not willing to come to New York City for in-person visits outlined\n* Plans to be out of town more than 2 consecutive weeks or \\>6 weeks total over the next 6 months\n* Type 1 or 2 diabetes; uncontrolled diabetes (e.g., HbA1c \\> 6.4% if specified); recurrent severe hypoglycemia or hypoglycemia unawareness.\n* Moderate-to-severe chronic kidney disease (e.g., eGFR \\\u003C 45-60 mL\u002Fmin\u002F1.73 m2 final cutoff per protocol) or other renal disease\n* Decompensated cirrhosis, severe chronic liver disease, or active liver disease\n* Unstable cardiovascular disease (e.g., myocardial infarction (MI), stroke, coronary revascularization, or hospitalization for unstable angina or decompensated heart failure (HF) within \\\u003C6 months)\n* Active malignancy requiring systemic therapy in the past 6-months (excluding non-melanoma skin cancer)\n* Serious medical\u002Fpsychiatric conditions making participation unsafe or likely to impair adherence\n* Pregnant, planning pregnancy within 6 months, or breastfeeding; women of childbearing potential unwilling to use effective contraception per institutional\u002Fdrug-label guidance.\n* Conditions requiring protein restriction (e.g., advanced Chronic Kidney Disease (CKD), relevant inborn errors of metabolism).\n* Severe, poorly controlled gout\u002Fhyperuricemia\n* Significant GI disease impairing tolerance or absorption (e.g., active Inflammatory Bowel Disease (IBD) with frequent flares, short bowel syndrome, severe gastroparesis beyond expected GLP-1 effects)\n* Severe food allergies or intolerances that preclude a high-protein diet or ingestion of whey or pea protein and associated additives\u002Fingredients of the protein powders used in this study.\n* Has or previously had an eating disorder\n* Severe musculoskeletal, neuromuscular, or other conditions that preclude moderate-intensity RT\n* Advised not to exercise by their general practitioner or medical professional or refusal to obtain medical clearance if indicated by Physical Activity Readiness Questionnaire (PAR-Q) answers\n* Standard contraindications to MRI: tattoos with metallic ink, pacemaker, cerebral and\u002For cochlear implant, metal in the eye, severe claustrophobia, presence of electronic devices or ferromagnetic metallic foreign or implanted objects that could constitute a hazard, inability to lie flat, or any other contraindication for MRI.\n* Weight \\>200kg, or large body habitus which the MRI scanner cannot accommodate.\n* Inability or unwillingness to attend a reasonable proportion of RT sessions and refusal of accommodations\n* Concurrent enrollment in another weight management intervention\n* Prior bariatric surgery within the past 12 months or planned bariatric surgery within the 6-month study period.\n* Active alcohol or drug use disorder\n* Significant cognitive impairment or language barrier precluding informed consent or adherence\n* Any reason that could compromise the participants' safety, based on the judgment of the investigators and\u002For clinical coordinators.","ALL","30 Years","60 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b) rhomboids, and upper and lower body muscle strength in adults recently prescribed tirzepatide. The secondary objectives of this study are to compare changes in resting energy expenditure (REE), adaptive thermogenesis (AT), and body adiposity (SFV, VAT, and intramuscular FF) in the quadriceps and rhomboid muscles) between the high-protein diet with RT and the high-protein diet arms at 6 months.",[26],"Weight Loss",[28,29],"GLP-1","tirzepatide","NOT_YET_RECRUITING","2026-07-07",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":20},"2026-07",{"date":38,"type":20},"2027-12",{"name":40,"class":41},"NYU Langone Health","OTHER",1,{"id":44,"slug":4,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100614224","NCT07276815","OverStitch NXT Endoscopic Suture System","Gathering of Results in Eligible Asian Obese Populations About Safety and Effectiveness of Overstitch ESG Trial","Inclusion Criteria:\n\n1. Aged 18 years or older, or subjects who have reached the legal age for signing informed consent in accordance with local laws and regulations.\n2. BMI ≥ 32.5 kg\u002Fm²; or BMI ≥ 27.5 kg\u002Fm² combined with type 2 diabetes mellitus (regardless of the effectiveness of medical treatment for type 2 diabetes); or BMI between 27.5 kg\u002Fm² and 32.5 kg\u002Fm² with ineffective medical weight loss or combined with other obesity-related diseases for which medical treatment is ineffective.\n3. Willing to comply with the long-term strict dietary restrictions required by the surgery.\n4. Capable of providing informed consent, able to complete all routine follow-up visits, and willing to abide by the protocol requirements, including signing the informed consent form, completing relevant examinations, and receiving dietary counseling.\n5. Females of childbearing potential (i.e., premenopausal or not sterilized) must agree to use adequate contraceptive measures.\n\nExclusion Criteria:\n\n1. History of foregut or gastrointestinal (GI) surgery (except uncomplicated cholecystectomy or appendectomy)\n2. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and\u002For adhesive peritonitis or known abdominal adhesions.\n3. Prior open or laparoscopic bariatric surgery.\n4. Prior surgery of any kind on the esophagus or any type of hiatal hernia surgery.\n5. Any inflammatory disease of the gastrointestinal tract including severe (LA Grade C or D) esophagitis, gastric ulceration, duodenal ulceration, specific inflammation such as Crohn's disease, and the doctor judges that it may affect the operation or efficacy of ESG.\n6. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresia or stenosis.\n7. History of gastrointestinal stromal tumors, gastrointestinal cancer, low-grade or high-grade gastric intraepithelial neoplasia, or familial or non-familial adenomatous polyposis syndrome.\n8. Gastric masses or untreated gastric polyps with a diameter \\> 1 cm.\n9. Hiatal hernia (Z-line displacement above the diaphragm \\> 4 cm) or severe\u002Frefractory gastroesophageal reflux symptoms, which the physician judges may affect the performance or prognosis of ESG.\n10. Structural abnormalities of the esophagus or pharynx that may impede endoscopic passage (e.g., strictures or diverticula), which the physician judges may affect the performance or prognosis of ESG.\n11. Gastrointestinal motility disorders (e.g., achalasia, severe esophageal motility disorders, gastroparesis, or intractable constipation), which the physician judges may affect the performance or prognosis of ESG.\n12. Evidence of untreated psychiatric or eating disorders, such as major depression, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.\n13. Coagulopathy with INR \\> 1.5 that cannot be corrected (per physician's judgment) or requirement for continuous full anticoagulant therapy, and\u002For any underlying diseases associated with high bleeding risk.\n14. Insulin-dependent diabetes mellitus (type 1 or type 2), or high likelihood of requiring insulin therapy within the next 12 months.\n15. Decompensated cirrhosis, or acute\u002Fchronic liver dysfunction that the physician judges make the subject unsuitable for ESG treatment.\n16. Diagnosis of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma) or immunocompromise, which the physician assesses may affect the performance or prognosis of ESG.\n17. Known history of endocrine diseases affecting body weight (e.g., Cushing's syndrome, uncontrolled hypothyroidism, or hyperthyroidism), which the physician assesses may affect the performance or prognosis of ESG.\n18. Anemia: Hemoglobin (Hgb) \\\u003C 110 g\u002FL for females; Hgb \\\u003C 120 g\u002FL for males.\n19. Any other medical conditions precluding elective endoscopy, such as poor general health, history of severe renal, hepatic, cardiac, and\u002For pulmonary diseases, and\u002For severe or uncontrolled psychiatric illnesses or abnormalities that may impair the patient's ability to understand or comply with follow-up visits and lifestyle interventions.\n20. Active psychological issues as determined by a psychologist or psychiatrist, precluding participation in lifestyle modification programs.\n21. Unwillingness to participate in the established medically supervised dietary and behavioral modification programs, as well as routine medical follow-up.\n22. Daily treatment with prescribed high-dose aspirin (\\> 80 mg per day), non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, corticosteroids, immunosuppressants, or other gastric irritant medications.\n23. Interval use of medications that may be affected by changes in gastric emptying (e.g., antiepileptic drugs or antiarrhythmic drugs).\n24. Inability or unwillingness to take prescribed proton pump inhibitor (PPI) medications.\n25. Current use of weight loss medications or other weight loss devices or use within the past 90 days.\n26. Current participation in a clinical trial involving investigational drugs or devices, or participation in such a trial within 30 days prior to enrollment in this study.\n27. Use of intragastric devices within 30 days prior to this study, which the physician assesses may affect the performance or prognosis of ESG.\n28. Unwillingness to avoid any reconstructive and\u002For plastic surgeries that may affect body weight during the study (e.g., mammoplasty, liposuction).\n29. Other conditions deemed unsuitable for endoscopy or ESG treatment by the investigator, including but not limited to conditions that the investigator believes may expose the subject to significant risks, confound study results, increase risks associated with endoscopy and\u002For endoscopic procedures, or substantially interfere with the subject's participation in the study.\n30. Pregnancy, lactation, or intention to become pregnant during the study (for females of childbearing potential).","18 Years",{"count":51,"type":20},136,[23],"To demonstrate the safety and efficacy of OverStitch NXT Endoscopic Suture System for endoscopic sleeve gastroplasty（ESG） in obese populations to support the registration of OverStitch NXT for ESG indication.",[26],"2026-06-28",{"date":57,"type":34},"2026-06-30",{"date":59,"type":20},"2026-07-31",{"date":61,"type":20},"2029-10-31",{"name":63,"class":64},"Boston Scientific Corporation","INDUSTRY",{"id":66,"slug":4,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":42},"100607988","NCT07195708","Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')","Clinical Study to Evaluate the Safety and Efficacy of the Orbera365 Intragastric Balloon System in Obese Patients","Inclusion Criteria:\n\n1. The subject is diagnosed with obesity, and the body mass index (BMI) is ≥28 kg\u002Fm² and ≤50 kg\u002Fm².\n2. The subject is aged ≥18 years.\n3. Failed previous conservative weight loss alternatives (e.g., supervised diet, exercise, and behavior modification programs).\n4. Willing to avoid the use of medical devices, medications, or other substances for weight loss purposes during the study period.\n5. Willing to avoid the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the study period, including aspirin, diclofenac, ibuprofen, naproxen, or other known gastric-irritating drugs.\n6. Able to take proton pump inhibitors (PPIs), antiemetics, and other medications as prescribed by the researcher.\n7. Capable of walking completely independently, with no severe chronic orthopedic diseases.\n8. Willing to undergo gastroscopy.\n9. Voluntarily participate in the trial, sign the informed consent form, and be willing to comply with study requirements, including follow-ups.\n\nExclusion Criteria:\n\n1. Prior surgery involving the esophagus, stomach, and duodenum.\n2. Prior bariatric surgery or intragastric medical devices for weight loss.\n3. A large hiatal hernia of \\> 5 cm or a hernia ≤ 5 cm associated with severe or intractable gastroesophageal reflux symptoms.\n4. Patients who have a history of gastrointestinal obstruction, adhesive peritonitis.\n5. Any active inflammatory or neoplastic disease of the gastrointestinal tract. among these, inflammatory diseases include esophagitis, gastric ulcer, duodenal ulcer, and specific types (e.g., Crohn's disease), while neoplastic diseases include cancer, and the doctor judges that such conditions may affect the use of Orbera365.\n6. Potential upper gastrointestinal bleeding disorders, such as esophageal or gastric varices, congenital or acquired intestinal capillary ectasia, or other congenital gastrointestinal abnormalities, such as atresia or stenosis that precludes the usage for Orbera365.\n7. A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and\u002For an endoscope that precludes the usage for Orbera365.\n8. Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.\n9. Positive result in the Helicobacter pylori breath test (Patients who turn negative after regular treatment can participate in this clinical trial).\n10. History or symptoms of uncontrolled or unstable thyroid disease.\n11. Abnormal coagulation with an INR \\> 1.5 that cannot be corrected (as judged by a physician) or requiring continuous full anticoagulant therapy, and\u002For the presence of any underlying disease associated with a high risk of bleeding.\n12. Hepatic insufficiency or liver cirrhosis, including: acute liver failure, advanced liver cirrhosis with encephalopathy, muscle atrophy, and generalized edema. severe esophageal varices with red signs and gastric varices. severe portal hypertensive gastropathy with or without gastric antral vascular ectasia.\n13. Anemia: For females, hemoglobin (Hgb) \\\u003C 110 g\u002FL. for males, hemoglobin (Hgb) \\\u003C 120 g\u002FL.\n14. Patients with known or suspected allergic reactions to the materials contained in Orbera365.\n15. Any other physical conditions that do not allow for elective endoscopy, such as poor overall health or a history and\u002For symptoms of severe kidney, liver, heart, and\u002For lung diseases. severe or uncontrolled mental illnesses or abnormalities that may affect the patient's ability to understand or comply with follow-up visits and the removal of the device 12 months later.\n16. Patients who are unable or unwilling to take the prescribed proton pump inhibitor medications during the device placement period.\n17. Patients who are unwilling to avoid any reconstructive and\u002For plastic surgeries that may affect weight during the study period, such as mammoplasty and liposuction.\n18. Patients who are unwilling to participate in the established medical supervision diet and behavior modification program and undergo regular medical follow-ups.\n19. Patients who are receiving treatment with anticoagulants, antiplatelet drugs, immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), or other drugs known to irritate the gastroduodenal mucosa or reduce gastrointestinal motility and\u002For are unwilling to discontinue such concomitant medications. prescription or over-the-counter weight loss drugs, drugs known to cause significant weight gain or loss (such as anesthetics, opioids, or benzodiazepines), insulin, antiepileptic drugs, antiarrhythmic drugs (such as amiodarone). other drugs that may cause weight changes, including drugs that can significantly increase weight (such as glucocorticoids, insulin secretagogues, thiazolidinediones, atypical antipsychotics, sodium valproate, lamotrigine, antidepressants, etc.), and drugs that can significantly reduce weight (such as glucagon-like peptide-1 receptor agonists, α-glucosidase inhibitors, topiramate, fluoxetine, bupropion, zonisamide, etc.).\n20. Alcohol abuse and\u002For drug abuse.\n21. Evidence of untreated mental or eating disorders, such as major depressive disorder, schizophrenia, substance abuse, binge eating disorder, or bulimia nervosa.\n22. Poor overall health, presence of specific diseases, or situations that, in the judgment of the researcher during evaluation and\u002For device placement, may put the subject at significant risk, may confound the study results, may increase the risks associated with endoscopy and\u002For balloon placement, or may significantly interfere with the subject's participation in the study (for example, having acquired immunodeficiency syndrome or hepatitis C within the past 5 years).\n23. Pregnant, breastfeeding, or having the intention to become pregnant during the study period (for females of childbearing potential).\n24. Currently participating in a study of investigational drugs or devices, or having participated in such a study within 30 days before participating in this study.",{"count":72,"type":20},144,[23],"To demonstrate the safety and efficacy of Orbera365 in obese populations to support the registration of Orbera365.",[26],"RECRUITING",{"date":57,"type":34},{"date":79,"type":34},"2026-06-03",{"date":81,"type":20},"2028-12-31",{"name":63,"class":64},{"id":84,"slug":4,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":15,"minAge":49,"maxAge":17,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":42},"100113251","NCT00739362","Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment","The Effects of Transcranial Direct Current Stimulation (TDCS) on Food Intake and Weight Loss","* INCLUSION CRITERIA:\n* BMI \\>= 25 kg\u002Fm\\^2\n* Age 18-60 years. Women who are post-menopausal will be excluded from the study due to changes in their metabolism that could affect weight loss. We will set the cutoff at age 60 so that the age difference between the men and women is not too great for analysis purposes. Minors under the age of 18 will be excluded because the time requirements of the study are such that they would interfere with school schedules.\n* Right-handedness (because the treatment will be given to the left dorsolateral prefrontal cortex and the evidence accumulated in this region was only in right-handed individuals).\n* Weight stable (+\u002F- 5 percent) for last 3 months as determined by volunteer report.\n\nEXCLUSION CRITERIA:\n\n* Weight \\> 300 lbs (136 kg), as this is the general size limit of the fMRI machine. Participants \\>300 pounds may be included if their body habitus will allow them to fit within the diameter of the MRI machine. This will be determined on a case-by-case basis after consultation with staff at Banner Health Neuroimaging Center.\n* Use of medication affecting metabolism and appetite in the last three months\n* Current pregnancy, pregnancy within the past 6 months or currently lactating\n* History or clinical manifestations of acute or chronic disorders or conditions that may affect appetite or energy expenditure (such as, but not limited to type 1 or type 2 diabetes, Cushing s disease, thyroid disorders, coccidiomycoses)\n* Gastrointestinal disease, including inflammatory bowel diseases (e.g. Chron s disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active) which may alter metabolism\n* Current, unstable medical conditions such as hepatitis, renal insufficiency, cancer requiring treatment in the last 5 years, or central nervous system disorders etc. as assessed by history and physical exam\n* Evidence of alcohol abuse as defined by \\>= 8 point score on the Alcohol consumption screening AUDIT questionnaire in adults\n* Evidence of drug use such as amphetamines, cocaine, heroin, or marijuana\n* Current use of tobacco products that exceed \"Very Low Dependence\" on the Fagerstr(SqrRoot)(Delta)m Test for Nicotine Dependence Tool (score greater than 2)\n* Postmenopausal women or symptoms of perimenopause (e.g. hot flashes, onset of irregular periods following age 40, elevation of FSH \\>20 IU following age 40 years)\n* Any conditions contraindicated for MRI (e.g., pacemaker, metal in the cranial cavity, significant claustrophobia, holes in the skull made by trauma or surgery)\n* Any condition not specifically mentioned above that, in the opinion of the investigator, may interfere with the study or prove unsafe for participation.",true,{"count":91,"type":20},148,[93],"PHASE2","This study will determine whether electrical stimulation of an area of the brain called the dorsolateral prefrontal cortex, which is important in determining the feeling of fullness after eating, affects how much food a person eats and weight loss over 4 weeks. It will also compare weight changes in people who attend weight loss counseling sessions and those who do not over this period of time.\n\nObese, non-diabetic people between 18 and 60 years of age who are in good health and who live in the Phoenix, AZ, metropolitan area are eligible for this study. Candidates must have a body mass index of 35 kg\u002Fm(2) or more and weigh less than 350 pounds.\n\nParticipants are admitted to the NIH inpatient unit in Phoenix for the first 9 days of the study for tests, which include meal tests to determine eating behaviors and caloric intake, blood and urine tests, glucose tolerance test, weight measurement, psychological assessments and DEXA scan to measure body fat. For 3 of the days, they will be asked to eat all of their food from automated vending machines. Some subjects receive transcranial direct current stimulation (TDCS). For this procedure, electrodes that conduct electricity are placed on the head and arm and the current is turned on for 40 minutes. Some tingling may be felt under the electrodes. Other subjects receive sham TDCS, with the current turned on only very briefly.\n\nAfter the evaluations, subjects are discharged home from the NIH unit and instructed to eat 25 percent fewer calories than they consumed while on a weight maintenance diet the first 3 days of their inpatient stay. They maintain the lower calorie diet at home for 4 weeks. During this period they come to the NIH unit 3 days a week to receive either real or sham TDCS.\n\n...",[96,97,26,98],"Electric Stimulation Therapy","Obesity","Eating",[100,97,101,26,102],"Behavioral Weight Loss Treatment","Appetite Control","Transcranial Direct Current Stimulation (TDCS)","2026-06-27",{"date":57,"type":34},{"date":106,"type":34},"2009-01-19",{"date":108,"type":20},"2027-01-31",{"name":110,"class":111},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":113,"slug":4,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":42},"100634146","NCT07535892","Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Pilot Trial of a Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation","Inclusion Criteria:\n\n* Age 18 years or older\n* Loss of ≥15% of initial body weight using anti-obesity medication\n* Discontinued anti-obesity medication within the past 4 weeks or planning to discontinue prior to randomization\n* ≤3 kg weight regain within the past 3 months\n* Willing and able to participate in a 6-month behavioral intervention, including a 10-week foundational program\n* Willing to complete study assessments at baseline, 3 months, and 6 months, including required in-person visits\n* Medical clearance for participation in moderate physical activity, dietary modification, and mind-based practices\n* Access to reliable internet for participation in virtual sessions and remote data collection\n* English fluency sufficient to complete study procedures\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Medical conditions that would preclude safe participation in physical activity, dietary changes, or mind-based practices (e.g., unstable cardiovascular disease, uncontrolled hypertension, severe orthopedic limitations, or seizure disorders not medically managed)\n* Active psychiatric conditions that would interfere with participation or safety (e.g., untreated major depression, active substance use disorder, or psychosis)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study period\n* Current participation in another structured weight loss or weight maintenance program\n* Continued use of anti-obesity medication after randomization\n* Plans to initiate medications or treatments that may significantly affect body weight during the study period\n* Inability to attend required study visits or participate in virtual sessions and remote data collection\n* Any condition that, in the opinion of the investigators, would compromise participant safety or study integrity",{"count":119,"type":20},64,[23],"This study is a single-site, pilot randomized factorial trial designed to evaluate the feasibility, acceptability, participant perceptions and preliminary effects of a multi-component behavioral intervention to support weight loss maintenance following discontinuation of GLP-1 and other anti-obesity medications. The intervention includes a standardized 10-week foundational weight loss maintenance program combined with candidate support components, including medically tailored meals, YMCA membership, and a structured mind-based program. Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months. Findings from this pilot study will inform optimization of a scalable intervention for future clinical trials.",[26,123,124,125],"GLP - 1","Weight Loss Maintenance","Obesity & Overweight",[26,28,127,128],"Anti-Obesity Medication","weight loss maintenance","2026-06-23",{"date":131,"type":34},"2026-06-26",{"date":133,"type":20},"2026-11-01",{"date":135,"type":20},"2029-07-31",{"name":137,"class":41},"University of Alabama at Birmingham",{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100584833","NCT06894498","Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss","LIGHT","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age at the time of the ESG procedure\n* Subject with a BMI between 30 kg\u002Fm2 and 50 kg\u002Fm2, inclusive, at the time of the primary ESG procedure using Overstitch Endoscopic Suturing System\n* Subject completed follow-up 1-year from the ESG procedure for weight loss management\n* Subject completed or is eligible for follow-up 5-years from the ESG procedure for weight loss management (visit can be collected either retrospectively or prospectively)\n* Subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure.\n* Subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate)\n* Subject is able to read, understand, and sign a written Informed Consent Form to participate in the study\n\nExclusion Criteria:\n\n* None",{"count":145,"type":20},100,"OBSERVATIONAL","The objective of this study is to assess the long term weight loss and weight loss journey of patients who received an Endoscopic Sleeve Gastroplasty (ESG) 5 or more years prior to enrollment.",[149,26],"Obesity and Obesity-related Medical Conditions",{"date":151,"type":34},"2026-06-25",{"date":153,"type":34},"2026-03-31",{"date":155,"type":20},"2026-12",{"name":63,"class":64},8,{"id":159,"slug":4,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":186,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist",{"count":165,"type":20},132,[23],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[97,169,170,171,172,173,174,175,26,176,177,178,179,180,181,182,183,184,185],"Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[187,188,189,190,191,192,193,194,195,196,197,198,199],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)",{"date":151,"type":34},{"date":202,"type":34},"2025-06-24",{"date":204,"type":20},"2028-06",{"name":206,"class":41},"Pichamol Jirapinyo, MD, MPH",2,{"id":209,"slug":4,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":42},"100548638","NCT06423599","Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","FIT-HF","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years at the time of signing informed consent\n* Body mass index (BMI) ≥ 30 kg\u002Fm2\n* Heart failure with New York Heart Association (NYHA)-class 1-3 and reduced ejection fraction (EF≤40%) established by either:\n\n  1. echocardiography AND\u002FOR\n  2. cardiac magnetic resonance\n* On stable optimal medical heart failure therapy for at least 4 weeks\n\nExclusion Criteria:\n\n1. Cardiovascular-related:\n\n   * Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 6 months prior to the day of screening\n   * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n   * Transient heart failure related to reversible mechanisms like tachycardia, sepsis, etc.\n2. Glycaemia-related:\n\n   * Type 1 diabetes\n   * Treatment with any Glucagon-Like Peptide-1 (GLP-1) agonists within 90 days prior to the day of screening\n   * Type 2 diabetes requiring other pharmacotherapy than metformin and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors\n3. General safety:\n\n   * Pregnancy or planned pregnancy\n   * History or presence of chronic pancreatitis\n   * Presence of acute pancreatitis within the past 180 days prior to the day of screening\n   * Kidney disease with eGFR \\\u003C 35ml\u002Fmin\n   * Presence or history of malignant neoplasms within the past 5 years prior to the day of screening (Basal and squamous cell skin cancer and any carcinoma in-situ are allowed)\n   * Known or suspected hypersensitivity to trial product(s) or related products",{"count":145,"type":20},[93,216],"PHASE3","The benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including overweight, dysglycaemia and hypertension in subjects with type 2 diabetes (T2D). The STEP-HFpEF (Semaglutide Treatment Effect in People With Obesity and HFpEF) recently demonstrated, at 1-year, to not only reduce weight considerably, but also significantly improve health-related quality of life, functional status scores and 6-min walk distance in patients with heart failure with preserved ejection fraction (HFpEF). Also, the recently concluded SELECT trial was the first CV outcome trial with semaglutide in patients with overweight or obesity and established CV disease, including heart failure (but no T2D). Semaglutide demonstrated a 20% reduction in MACE, defined as the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.\n\nThese landmark findings have important implications for clinicians -as they mean that weight loss and\u002For semaglutide as anti-obesity pharmacotherapy could be a treatment strategy for secondary prevention of CV disease in patients with overweight or obesity.\n\nIt is, however, unknown whether weight loss with either calorie-restricted diet or semaglutide has beneficial effects in obese subjects with heart failure and reduced ejection fraction. Also it is unclear whether semaglutide has cardiovascular benefits irrespective of starting weight and amount of weight loss.\n\nPurpose: The study aims to investigate whether weight loss treatment with semaglutide is superior to weight loss with calorie-restricted diet in improving peak oxygen uptake in patients with obesity and heart failure with reduced ejection fraction.",[219,97,26,220],"Heart Failure With Reduced Ejection Fraction","Chronic Heart Failure","2026-06-22",{"date":129,"type":34},{"date":224,"type":34},"2024-04-30",{"date":226,"type":20},"2027-12-30",{"name":228,"class":41},"Jens D Hove, MD,PHD",{"id":230,"slug":4,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100594129","NCT07015424","Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass","Prospective, Randomized Clinical Study Evaluating Transoral Outlet Reduction (TORe) and Lifestyle Modification for Patients With Weight Regain Following Roux-en-Y Gastric Bypass","REIGNITE","Inclusion Criteria:\n\n* 18 years or older.\n* Experiencing weight regain (≥ 20% weight from nadir) after achieving clinically successful weight loss.\n* Willing to have a TORe procedure for the treatment of weight regain.\n* BMI between 30 and 50 kg\u002Fm2, inclusive.\n* GJA diameter ≥ 20 mm, confirmed either during a\n* Screening EGD completed ≤ 60 days from study procedure or\n* EGD performed immediately prior to the TORe procedure.\n* Anatomically accepting of the procedure, including a pouch size that will not require reduction at the time of treatment (pouch that is shorter than 6 cm in length).\n* Agrees not to take additional over the counter or prescribed weight loss supplements \u002F medications (including incretins) during the first 6 months of the study.\n* Is on a stable dose of anti-diabetic medication for three months with no anticipated changes during the first 6 months of the study.\n* Agrees to the follow-up requirements of the study and is able to read, understand, and sign a written Informed Consent Form to participate in the study.\n* Meets the indications for TORe procedure with OverStitch™ Endoscopic Suturing System.\n\nExclusion Criteria:\n\n* Current use or use within the three months prior to the baseline visit of over the counter or prescribed weight loss supplements \u002F medications (including incretins).\n* Current or planned management of Type 2 Diabetes with incretin medications.\n* Inability or unwillingness to comply with assigned treatment or protocol requirements related to visits.\n* Investigator's medical judgement that the subject is not a candidate for the TORe procedure.\n* Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding in the next two years.\n* Vulnerable subject.",{"count":237,"type":20},108,[23],"The goal of this clinical trial is to evaluate weight loss with TORe and intensive lifestyle modification versus intensive lifestyle modification alone in subjects who have regained weight following a Roux-en-Y gastric bypass.\n\nParticipants will randomized 2:1. Those randomized to the TORe arm will receive a TORe procedure and intensive lifestyle modification which consists of a well-balanced calorie restrictive diet, incorporation of exercise and coaching on lifestyle discussion. Participants randomized the lifestyle modification alone arm will be eligible to receive a TORe procedure at 6 months post enrollment. Total follow up will be 24 months.",[241,26],"Weight Regain",[243,244],"TORe","OverStitch","2026-06-11",{"date":247,"type":34},"2026-06-12",{"date":249,"type":34},"2026-04-14",{"date":251,"type":20},"2028-11",{"name":63,"class":64},9,{"id":255,"slug":4,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":42},"100424854","NCT04812314","Exercise Effects on Adipose Tissue Structure and Function","LG","Inclusion Criteria:\n\n* Age: 18-40\n* Body Mass Index: 27-45 kg\u002Fm2\n* No regularly planned exercise\u002Fphysical activity for at least 6 months\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion Criteria:\n\n* Evidence\u002Fhistory of cardiovascular or metabolic disease\n* Medications known to affect lipid or glucose metabolism, or inflammation\n* Weight instability ≥ ± 6 pounds in the last 3 months\n* Tobacco or e-cigarette users\n* Women must not be pregnant or actively lactating","40 Years",{"count":262,"type":20},46,[23],"Participants will be randomized into one of two different experimental groups: 1) Exercise group and 2) No exercise (control group). Subject participation in the study will involve a series of metabolic tests before and after participants undergo a 10% weight loss program (with or without exercise training depending on group randomization). After completing this weight loss portion of the study, participants will then be required to adhere to a high calorie diet program to regain half of the weight the participant lost - followed by the same series of metabolic tests.",[97,266,179,176,26,267],"Metabolic Syndrome","Weight Gain","2026-06-02",{"date":270,"type":34},"2026-06-04",{"date":272,"type":34},"2021-03-01",{"date":274,"type":20},"2030-03-01",{"name":276,"class":41},"University of Michigan",{"id":278,"slug":4,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":89,"sex":15,"minAge":49,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":42},"100634520","NCT07540754","A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","Inclusion Criteria:\n\n1. Participants must fully understand and voluntarily sign a written informed consent form before the trial, demonstrating comprehension of the trial content, procedures, and potential adverse reactions; they must also be willing and able to comply with the protocol requirements to complete the study.\n2. Female participants of childbearing potential must have a negative baseline serum pregnancy test, must not be lactating, and must agree to use contraceptive measures and refrain from egg donation from the time of signing the informed consent form until 2 months after the last dose of the study drug; male participants with partners of childbearing potential must agree to use contraceptive measures and refrain from sperm donation from the time of signing the informed consent form until 2 months after the last dose of the study drug.\n3. Aged 18 to 65 years (inclusive), both male and female.\n4. Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. Body mass index (BMI) is within the range of 19.0 to 40.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. Participation in any clinical trial of a drug or medical device within 3 months prior to dosing, or currently within the follow-up period of a clinical study or within 5 half-lives of the investigational drug (whichever is longer).\n2. Allergic constitution, including a history of severe drug allergy or drug anaphylaxis, excluding untreated asymptomatic seasonal allergies or individuals with positive skin tests only.\n3. Smokers and drinkers who are unable to abstain during the trial period; positive alcohol screening test.\n4. Drug abusers or those with a positive urine drug screening test.\n5. Blood loss or blood donation ≥400 mL within 3 months prior to dosing, or blood loss or blood donation ≥ 200 mL within 1 month prior to dosing, or receipt of a blood transfusion within 3 months prior to dosing.\n6. Undergone any surgery within 6 months prior to dosing, or planned to undergo surgical procedures during the study period.\n7. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia).\n8. History of severe hypoglycemia.\n9. Previous significant gastric emptying abnormalities or factors affecting gastric emptying (e.g., history of gastric bypass surgery, pyloric stenosis), or severe gastrointestinal diseases (e.g., active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (excluding surgeries with no significant impact on gastrointestinal motility, such as removal of gastrointestinal polyps, appendectomy, hemorrhoidectomy, etc.).\n10. Anyone with factors making them unsuitable to participate in this trial evaluated by the investigator.","65 Years",{"count":285,"type":20},24,[287],"PHASE1","This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild\u002Fmoderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.",[290,26],"Diabetes Mellitus","2026-05-28",{"date":293,"type":34},"2026-06-01",{"date":295,"type":34},"2026-05-26",{"date":297,"type":20},"2027-02",{"name":299,"class":64},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":301,"slug":4,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":314,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":42},"100639482","NCT07601061","Simplifying Diet Tracking in a Digital Weight Loss Intervention","Simplifying Dietary Self-Monitoring in a Digital Weight Loss Intervention","Inclusion Criteria:\n\n* adults (ages 18+ years)\n* body mass index (BMI) 25.0 to 45.0 kg\u002Fm\\^2\n* smartphone ownership\n* willing to install a mobile app on personal smartphone\n* access to a personal email account\n* English or Spanish language proficiency\n* interest in losing weight through behavioral strategies\n* living in the United States\n* willing to be randomized\n\nExclusion Criteria:\n\n* concurrent enrollment in another weight management intervention\n* loss of ≥5% weight in the past 6 months\n* prior or planned bariatric surgery during the trial period\n* current or planned pregnancy during the trial period, or recent pregnancy in the past 6 months\n* currently breastfeeding or lactating\n* current use of anti-obesity medications\n* living with someone else participating in the study\n* hospitalization for a mental health condition in the past 12 months\n* inability to engage in moderate forms of physical activity akin to brisk walking\n* medical or psychiatric contraindication (e.g., end stage renal disease, cancer, schizophrenia, dementia, use of steroids, use of antipsychotic medication)\n* if an individual would be better suited for a more intensive or different type of intervention based on a health condition (e.g., individuals with history of an eating disorder or cardiovascular event, uncontrolled hypertension, or uncontrolled diabetes mellitus)\n* investigator discretion for safety reasons",{"count":307,"type":20},328,[23],"The purpose of this study is to compare two approaches for tracking dietary intake in a 12-month fully digital weight loss intervention: (1) Simplified approach: track Red Zone Foods (e.g., foods high in calories and low in nutritional value) vs. (2) Detailed approach: track all foods and their corresponding calories. In essence, this is a head-to-head comparison of two tracking approaches; the investigators are evaluating whether weight loss is comparable over 12 months, or whether one approach will have greater weight loss.\n\nThe investigators will recruit 328 adults. Broadly, adults with overweight or obesity who live in the United States will be eligible. The weight loss intervention will last 12 months. All participants will be asked to track their dietary intake + body weight + steps daily as well as complete weekly behavioral lessons and action plans to promote healthy eating and physical activity. All study tasks will occur remotely. Assessment of body weight and survey measures will occur at the beginning of the trial (\"baseline\"), and at 1, 6, 12, and 18 months.",[311,97,26,312,313],"Overweight","Health Behavior","Lifestyle Intervention",[315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348],"digital intervention","behavioral intervention","behavior change","obesity","body weight","overweight","BMI","diet","tracking","track","self-monitoring","self-monitor","lifestyle","adults","intervention","weight loss","weight loss intervention","weight reduction","weight management","red zone foods","calorie counting","noninferiority trial","non-inferiority","comparative effectiveness trial","comparative effectiveness","RCT","randomized clinical trial","digital health","mobile health","obesity treatment","obesity management","remote intervention","standalone intervention","standalone","2026-05-22",{"date":291,"type":34},{"date":352,"type":20},"2027-05-01",{"date":354,"type":20},"2030-10-31",{"name":356,"class":41},"Stanford University",{"id":358,"slug":4,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":367,"conditions":368,"keywords":372,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":42},"100640329","NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","FLOURISH","Inclusion Criteria:\n\n* Speaks English\n* Community-dwelling, community-living status\n* Able to ambulate independently, with or without aids or devices\n* Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities\n* Provides informed consent for study participation\n* Commitment and willingness to participate, as assessed by completion of decisional balance exercise\n* Program-specific eligibility:\n* Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.\n* Noom Weight only: Individual who is not interested in medication\n* Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier\n\nExclusion Criteria:\n\n* Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)\n* GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)\n* Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program\n* Previous or planned (during the 12-month study) bariatric surgery\n* Active eating disorder\n* Active cancer\n* Type 1 diabetes or current Insulin use\n* Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)\n* Depression screen results in a PHQ-8 score of 20 or greater.\n\nAll medicated arms and Noom Weight arms (only):\n\n\\- Purchased more than the base Noom program offered for participant's specific arm\n\nGLP-1 Medication Arms Only:\n\n* GLP-1 agonist use is contraindicated (per program criteria) in members with:\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)\n* Personal history of Pancreatitis","64 Years",{"count":366,"type":20},2310,"This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.\n\nFLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).\n\nTHRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.\n\nParticipants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.",[125,26,369,370,371],"Preventative Health","Body Weight","Cardiovascular Disease Risk Factor",[28,373,374,375,376,377,378,379,380,29,381,342,330,382,383],"Microdose","weight","body composition","metabolic","biomarkers","longevity","glucagon-like peptide-1","semaglutide","microdosing","behavioral health","real world evidence","2026-05-08",{"date":386,"type":34},"2026-05-15",{"date":388,"type":20},"2026-04-30",{"date":390,"type":20},"2029-05",{"name":392,"class":64},"Noom Inc.",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":89,"sex":15,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":21,"phases":404,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":42},"100589043","NCT06949280","Metabolic Health, Bones and Nuts During Weight Loss in Adults","Metabolic Health, Bones and Nuts Sources of Fatty Acids During Weight Loss in Adults","BERN","Inclusion Criteria:\n\n* Men and postmenopausal women (\\>2 years since last menses), ages 50-75 years\n* Body mass index (25-42 kg\u002Fm2) or evidence of pre-clinical obesity.\n* Agree to be randomly assigned to consume a daily peanut snack or nut-free snack for 24 weeks\n* Must attend on-site visits (about 10) in New Brunswick, NJ, USA (transportation\u002Freimbursement for travel not included)\n\nExclusion Criteria:\n\n* Peanut allergies or intolerances\n* Participants with \\>5% weight loss in the past 6 months or extreme dietary\u002Fphysical activity habits\n* An inability to follow the experimental intervention or to perform the required specimen collections.\n* Individuals with significant psychiatric or food disorders.\n* Current diagnosis, or history of cancer in past 3 years.\n* Current diagnosis or history of bone diseases, type I or II diabetes, gastrointestinal disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, cardiac, or renal disease.\n* Uncontrolled hypertension or hyperlipidemia in abnormal ranges.\n* History of surgery in the past 6 months or surgical procedure for weight loss in the past 3 years.\n* Regular use of medications that affect bone metabolism, including bisphosphonates or hormone replacement.\n* Regular use of medications for that affect the gastrointestinal tract including incretin mimetics, cholecystitis, urinary tract infection, severe organic diseases including coronary heart disease, myocardial infarction, infectious diseases including pulmonary tuberculosis and AIDS.\n* Antibiotic use in the past month\n* Alcohol or illicit drug abuse\n* Any other condition deemed by the Research Physician that would prevent participation in the study, e.g. participation in another clinical research project that may interfere with the results of this study.\n* Participation in another clinical interventional research trial","50 Years","75 Years",{"count":403,"type":20},44,[23],"The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.",[26,407,408],"Bone Density","Obesity and Overweight",[330,328,410,411,412,413,414,415],"bone","cognition","metabolic health","sleep","peanut","Monounsaturated fatty acid",{"date":417,"type":34},"2026-05-13",{"date":419,"type":34},"2025-10-30",{"date":421,"type":20},"2027-12-31",{"name":423,"class":41},"Rutgers, The State University of New Jersey",{"id":425,"slug":4,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":42},"100610161","NCT07223983","Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)","Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)\n* Age 18 and older\n* Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg\u002Fm2\n* Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years\n* Meet current DSM-5 criteria for Alcohol Use Disorder\n* Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators\n* Read, comprehend, and write English at a sufficient level to complete study-related materials\n* For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation\n\nExclusion Criteria:\n\n* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening\n* History or presence of chronic or recurrent pancreatitis\n* History of malignant neoplasms within the past 5 years prior to screening\n* Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n* Is currently using other medications for weight loss or other GLP-1 receptor agonists\n* Has a history of allergy or sensitivity to Semaglutide\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats\u002Fminute\n* Has current uncontrolled hypertension\n* Has current uncontrolled Type I or Type II diabetes mellitus\n* Has untreated hypothyroidism with a TSH \\> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit\n* Has active gallbladder disease\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder\n* Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months\n* Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use\n* Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device\n* Is breast-feeding, pregnant, or not using a reliable form of birth control\n* Reports active suicidal or homicidal ideation\n* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol",{"count":431,"type":20},10,[287],"The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.",[435,26,436],"Alcohol Use Disorder","Bariatric Surgery Patients","2026-05-07",{"date":439,"type":34},"2026-05-12",{"date":441,"type":34},"2026-03-06",{"date":443,"type":20},"2026-10-31",{"name":445,"class":41},"Yale University",{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":89,"sex":15,"minAge":49,"maxAge":283,"enrollmentInfo":452,"targetDuration":4,"studyType":21,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":42},"100639615","NCT07577765","Testing a Tailored Approach to Long-Term Weight Loss Success","Pilot Testing an Adaptive Intervention for Weight Loss Maintenance","Inclusion Criteria:\n\n* BMI of ≥ 27 prior to weight loss\n* Lost ≥ 7% of body mass in the past 6 months\n* Weight loss was intentional\n* No plans for weight loss surgery in the next 6 months\n* Access to a smart device that can download applications and receive text messages\n* Able to receive clearance for study participation from primary care provider\n\nExclusion Criteria:\n\n* Pregnant or within 12 months postpartum, or planning pregnancy\n* Uncontrolled conditions that affect overall health (cardiovascular, metabolic, renal, pulmonary, psychiatric, thyroid, cancers)\n* Food insecure\n* Bariatric surgery or cancer treatment within the past 5 years\n* Active or recent (\\\u003C12 months) treatment\u002Fdiagnosis of an eating disorder",{"count":453,"type":20},30,[23],"The purpose of this study is to develop and test an adaptive, individually tailored intervention to prevent weight regain in people who have intentionally lost weight. The main questions it aims to answer are:\n\n* Is an adaptive intervention with tailored re-engagement support feasible for individuals following intentional weight loss?\n* Does this intervention prevent weight regain after intentional weight loss?\n\nParticipants will:\n\n* Complete a baseline assessment of body measurements\n* Complete surveys on dietary intake, mental health, and physical activity\n\nParticipants will also engage in a 26-week program, which involves:\n\n* Receive regular educational texts\u002Femails\n* Fill out weekly online survey check-ins\n* Weigh themselves at least weekly on a scale provided by the study\n* Some participants may receive health coaching during portions of the study.\n* Assessments will be repeated for all participants at the end of the intervention period.",[26,241,125],"2026-05-04",{"date":459,"type":34},"2026-05-11",{"date":461,"type":34},"2026-01-07",{"date":463,"type":20},"2027-09-01",{"name":465,"class":41},"University of Utah",{"id":467,"slug":4,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":473,"minAge":474,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":21,"phases":477,"briefSummary":478,"conditions":479,"keywords":496,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":509,"leadSponsor":511,"locationsCount":42},"100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","FEMALE","12 Years",{"count":476,"type":20},1040,[23],"The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[480,481,482,483,484,485,486,487,488,26,489,490,491,492,493,494,495],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Blood Pressure","Mental Health","Diarrhea","Coughing","Eczema","Allergies","Antibiotic Use",[497,498,499,500,501,502,503,504],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","2026-04-28",{"date":507,"type":34},"2026-05-06",{"date":293,"type":20},{"date":510,"type":20},"2028-02-28",{"name":512,"class":41},"Swiss Tropical & Public Health Institute",{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":89,"sex":15,"minAge":260,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":21,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":42},"100575730","NCT06776081","Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function","Adipocyte-Derived Extracellular Vesicles; Novel Biomarker and Mediator of Obesity-Related Endothelial Dysfunction","Inclusion criteria:\n\n* Age ≥40 years\n* BMI \\\u003C25 kg\u002Fm2 and BMI \\>25 kg\u002Fm2 for Phase 1 and BMI \\>25 kg\u002Fm2 for Phase 2. Rationale for defining obesity as BMI \\>25 kg\u002Fm2\n\nExclusion criteria:\n\n* Current smoker\n* Chronic overt medical condition (e.g., evidence of coronary artery disease on resting ECG, any history of myocardial infarction or stroke, or cancer, diabetes based on fasting blood glucose concentration)\n* Alcohol abuse or dependence defined as more than 14 standard drinks\u002Fweek and no more than 4 standard drinks\u002Fday for men and 7 standard drinks\u002Fweek and 3 standard drinks\u002Fday for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wines, 1 ½ ounces of 80-proof distilled spirits) reported during the medical history\u002Fphysical exam\n* Stage III hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Regular vigorous aerobic\u002Fendurance exercise (\\>3 bouts\u002Fweek, \\>30 minutes\u002Fbout at a workload \\>6 METS)\n* Women who are pregnant or breastfeeding\n* History of anaphylaxis to betadine, lidocaine, iodine\n* Raynaud's disease\n* History of clotting disorders\n* Anyone taking blood thinners and clotting medications\n* Anyone taking statin medication\n* Planned pregnancy in coming 4-6 months",{"count":520,"type":20},84,[23],"Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity.\n\nThe investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.",[97,26],[97,26],"2026-04-27",{"date":505,"type":34},{"date":528,"type":34},"2024-07-01",{"date":530,"type":20},"2027-06-30",{"name":532,"class":41},"University of Colorado, Boulder",{"id":534,"slug":4,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":11,"sex":15,"minAge":539,"maxAge":283,"enrollmentInfo":540,"targetDuration":4,"studyType":21,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":42},"100365290","NCT04036331","Dyad Plus Effectiveness\u002FFeasibility","Effectiveness\u002FFeasibility of A Coordinated Parent\u002FChild Dyad Weight Loss Intervention:","Inclusion Criteria:\n\n* Eligible for enrollment in Brenner FIT and\u002For By Design Essentials\n* Caregiver who lives in the house with a BMI \\> 30\n* No contraindication for physical activity or caloric restriction\n* Must be able to read and write English\n\nExclusion Criteria:\n\n* BMI \\\u003C 30\n* Contraindication for physical activity or caloric restriction\n* Cannot read or write English","13 Years",{"count":541,"type":20},90,[23],"The purpose of this research is to determine the effectiveness of a coordinated program (Dyad Plus) that would help to facilitate self-monitoring, positive communication, joint problem solving, and social support to increase physical activity, healthy eating, and weight loss. Participants of the Brenner FIT (Families In Training) pediatric weight management program and their parent\u002Fguardian will co-enroll in weight loss programs. Parents\u002Fguardians will receive the components of By Design Essentials.",[26,545,546,547,548],"Pediatric Obesity","Overweight Adolescents","Parent-Child Relations","Family and Household",{"date":505,"type":34},{"date":551,"type":34},"2021-07-30",{"date":36,"type":20},{"name":554,"class":41},"Wake Forest University Health Sciences",{"id":556,"slug":4,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":17,"enrollmentInfo":562,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":583},"100610560","NCT07229170","Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients","Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.","GLP1-TASTE","Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment.\n\nExclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.",{"count":563,"type":20},150,"This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of GLP-1 agonist treatment. The study's primary goal is to understand how these treatments affect food preferences and taste perception. Secondary outcomes include changes in body weight, body composition, gastrointestinal side effects, and treatment adherence. All data are anonymized and collected according to ethical guidelines.",[125,566,26,567],"Taste Alterations","Eating Behavior Changes",[569,570,571,572,573,574],"GLP-1 agonists","Obesity treatment","Weight loss","Taste perception","Eating habits","Observational study","2026-04-22",{"date":505,"type":34},{"date":578,"type":34},"2025-12-01",{"date":580,"type":20},"2028-01-01",{"name":582,"class":41},"San Raffaele Telematic University",4,{"id":585,"slug":4,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":42},"100400424","NCT04494048","Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry","EBT","Inclusion Criteria:\n\n* Any patient who is considering undergoing EBT for weight loss within 6 months, or has undergone clinically indicated EBT for weight loss within the past 6 months\n* Above or equal to 18 years of age.\n\nExclusion Criteria:\n\n* Any patient who has not undergone or will undergo EBT for weight loss\n* Below 18 years of age.","89 Years",{"count":592,"type":20},9999,"The purpose of this registry study is to collect data through medical chart review and in patient visits on the efficacy and safety of various Endoscopic Bariatric therapies (EBTs). This is a retrospective and prospective, observational, medical chart review study for at least 6 standard of care visits up to 1 years after a subject consents for study participation.",[97,26,595,596],"Gastro Esophageal Reflux","Bariatric Surgery Candidate","2026-04-21",{"date":599,"type":34},"2026-04-23",{"date":601,"type":34},"2016-04-05",{"date":603,"type":20},"2035-10-31",{"name":605,"class":41},"Weill Medical College of Cornell University",{"id":607,"slug":4,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":89,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":42},"100604075","NCT07144800","Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)","Inclusion Criteria:\n\nPhase 1\n\n* Age \\>= 18 years (per self-report)\n* Self-identifies as Hispanic\u002FLatino (per self-report)\n* Seeking, or has used, services at the VDS or MHU (per self-report)\n* Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)\n* Screens as obese (BMI \\> 30 kg\u002Fm2) or overweight (BMI of 25 - 29.9 kg\u002Fm2) (per height and weight measurement in person or per self-report)\n* Owns a cell phone capable of receiving text messages (per self-report)\n* Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)\n* Agrees to be audio-recorded (per self-report)\n\nPhase 2 (parent participants)\n\n* Age \\>= 18 years (per self-report)\n* Self-identifies as Hispanic\u002FLatino (per self-report)\n* Seeking, or has used, services at the VDS or MHU (per self-report)\n* Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)\n* Screens as obese (BMI \\> 30 kg\u002Fm2) or overweight (BMI of 25 - 29.9 kg\u002Fm2) (per height and weight measurement in person or remotely)\n* Owns a cell phone capable of receiving text messages (per self-report)\n* Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)\n* Agrees to be audio-recorded (per self-report)\n\nPhase 2 (child participants)\n\n* Age 8-12 years (per parent self-report)\n* Has a parent or primary caregiver who is eligible and participating in Phase 2 (per parent self-report)\n\nExclusion Criteria:\n\nPhase 1\n\n* Is pregnant or might be pregnant (per self-report)\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)\n* Has dietary restrictions, i.e. liquid diet, that may affect diet and study participation (per self-report)\n* Has a household member who has already participated or agreed to participate in this study program (per self-report)\n* Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups\n* Works for or with the VDS or MHU (per self-report)\n* Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection (per study team)\n\nPhase 2 (parent participant)\n\n* Is pregnant or might be pregnant (per self-report)\n* For women, is lactating (per self-report)\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)\n* Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per self-report)\n* Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (increasing step counts; per self-report)\n* Has a household member who has already participated or agreed to participate in this study program (per self-report)\n* Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups\n* Works for or with the VDS or MHU (per self-report)\n* Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection (per study team)\n\nPhase 2 (child participant)\n\n* Has dietary restrictions, i.e., liquid diet, that may affect diet and study participation (per parent self-report)\n* Has physical activity restrictions, i.e., handicapped or mobility issues, that may affect physical activity participation (per parent self-report)\n* Has an eating disorder (per parent self-report)\n* Is underweight (per parent self-report)",{"count":612,"type":20},1319,[23],"The purpose of this study is to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families. FCI is a type of program that involves family (such as parents and caregivers) supporting their children to promote healthy habits.",[97,616,26],"Child Obesity",[618,318,330,619,620],"child obesity","Memorial Sloan Kettering Cancer Center","25-003",{"date":622,"type":34},"2026-04-15",{"date":624,"type":34},"2025-08-22",{"date":626,"type":20},"2031-07-31",{"name":619,"class":41},{"id":629,"slug":4,"hasResults":11,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":11,"sex":15,"minAge":400,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":21,"phases":636,"briefSummary":637,"conditions":638,"keywords":642,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":42},"100578440","NCT06811324","Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults","The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults","Inclusion Criteria\n\n* Men and postmenopausal women aged 50 years or older.\n* Body Mass Index (BMI) ≥30 kg\u002Fm².\n* Untreated HbA1c \\\u003C6.5% at baseline.\n* Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.\n* Able to provide informed consent and participate in all study assessments.\n\nExclusion Criteria\n\n* Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.\n* Body Mass Index (BMI) ≥ 40 kg\u002Fm².\n* Moderate to severe gastroesophageal reflux disease based on patient history.\n* Inability to comply with the treatment protocol or to understand the consent form.\n* Chronic Kidney Disease (CKD) Stage 4.\n* Aspartate aminotransferase (AST) \\> 33 U\u002FL or alanine aminotransferase (ALT) \\> 36 U\u002FL.\n* Active pregnancy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal or family history of multiple endocrine neoplasia type 2 syndrome.\n* Personal history of gastroparesis.\n* Personal history of diabetic retinopathy.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies.\n* Concomitant treatment with GLP-1 receptor agonist therapy",{"count":635,"type":20},20,[93],"Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.",[639,640,641,123,26],"Obesity Prevention","Sarcopenia in Elderly","Cardiovascular Function",[643,28,97,644,641],"Tirzepatide","Sarcopenia","2026-04-10",{"date":622,"type":34},{"date":648,"type":34},"2026-04-01",{"date":650,"type":20},"2027-06-01",{"name":652,"class":41},"The University of Texas Health Science Center at San Antonio",{"id":654,"slug":4,"hasResults":11,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":89,"sex":15,"minAge":659,"maxAge":4,"enrollmentInfo":660,"targetDuration":4,"studyType":21,"phases":661,"briefSummary":662,"conditions":663,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":207},"100559513","NCT06565104","The Sleep2BWell Trial","Adding Sleep to the BWell4Life Diet and Physical Activity Intervention for Cardiometabolic Health Promotion: The Sleep2BWell Community-Based Trial","Inclusion Criteria:\n\n1. English- and\u002For Spanish-speaking\n2. aged ≥20 years\n3. having at minimum SBP in the elevated or hypertension category (i.e., SBP ≥120 mmHg)\n\nExclusion Criteria:\n\n1. No known medical conditions that would prevent them from safely participating in the trial (e.g., neurological degenerative disease such as Parkinsons, severe psychiatric disorders, substance use disorder)\n2. History of cardiovascular disease or cancer\n3. Pregnant or desire to become pregnant during the study\n4. Less than one year postpartum","20 Years",{"count":563,"type":20},[23],"Improving multiple domains of cardiometabolic health (CMH) through contextual behavioral interventions has the potential to substantially reduce persistent chronic disease disparities. Sleep is critical for preserving CMH and is amenable to intervention in real-world settings. Although sleep health, in conjunction with other lifestyle behaviors, can improve CMH through complementary or synergistic pathways, most existing lifestyle change programs focus solely on diet and physical activity. Sleep2BWell is a community-based cluster randomized trial aimed at evaluating the impact of incorporating a multidimensional sleep health intervention into the BWell4Life program, an ongoing 4-week program for promoting CMH through healthy diet and physical activity, delivered by peer health educators at faith-based organizations and community centers in underserved NYC neighborhoods. The enhanced 6-week intervention, Sleep2BWell, will include the following additional components: 1) two sleep health education and group coaching sessions, 2) self-monitoring and motivational enhancement using a Fitbit, and 3) addressing prevalent environmental barriers to healthy sleep in urban settings such as noise and light with a novel and timely extension to address indoor air pollution. A total of 10 community sites will receive the intervention enrolling an average of 15 participants per site for an expected sample of 150. The investigators will collect objective measures of sleep and physical activity throughout the study, and assess diet and CMH outcomes at baseline and 10 weeks (primary endpoint). The investigators hypothesize that Sleep2BWell will improve CMH, including reduced blood pressure (primary outcome) improved health behaviors (sleep, diet, physical activity) and adiposity markers (secondary outcomes). To ensure the successful completion and future expansion of this work, this study will use mixed methods to understand implementation determinants and outcomes, guided by implementation science frameworks. This first-of-its-kind effectiveness-implementation study, addressing individual level behaviors and factors and upstream influences and leveraging key behavior change and community engagement strategies, will investigate the integration of sleep health into a multi-behavior lifestyle change intervention aimed at addressing CMH disparities in community settings. This innovative multilevel intervention will inform scalable sustainable community health approaches and public health policy to improve sleep health and CMH disparities through advancement in novel multilevel bundled behavioral interventions.",[489,664,665,666,26],"Sleep Health","Diet, Healthy","Physical Activity",{"date":249,"type":34},{"date":669,"type":34},"2025-01-25",{"date":671,"type":20},"2027-06",{"name":673,"class":41},"Columbia University",{"id":675,"slug":4,"hasResults":11,"nctId":676,"briefTitle":677,"officialTitle":677,"acronym":678,"eligibilityCriteria":679,"healthyVolunteers":89,"sex":15,"minAge":49,"maxAge":260,"enrollmentInfo":680,"targetDuration":4,"studyType":21,"phases":682,"briefSummary":683,"conditions":684,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":42},"100501249","NCT05806801","Metabolic Adaptations to Weight Loss With and Without Exercise","WAX","Inclusion criteria\n\n* Age: 18-40\n* Body Mass Index: 30-40 kg\u002Fm2\n* Weight stable (±3kg for greater than or equal to about 2 months)\n* No regularly planned exercise\u002Fphysical activity\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion criteria\n\n* EKG abnormalities\n* Evidence\u002Fhistory of cardiovascular disease, diabetes or other metabolic disease\n* Medications known to affect lipid or glucose metabolism\n* Pregnant or lactating\n* Tobacco or e-cigarette use\n* Prior experience of hypersensitivity to insulin, human albumin, and potassium chloride injection.\n* Allergies\u002Fhypersensitivity to local anesthetics of the amide type (e.g., lidocaine)\n* History of hyperkalemia or potential for developing hyperkalemia (including but not limited to taking drugs that may induce hyperkalemia such as cardiac glycosides or potassium sparing diuretics)\n* Anti-coagulant medication (e.g., Coumadin, Rivaroxaban) and Lidocaine allergy\u002Fsensitivity are exclusion criteria for the biopsy procedure.",{"count":681,"type":20},68,[23],"Study Purpose:\n\nThe combination of caloric restriction and exercise is the most common first-line treatment for obesity-related disorders, yet we know very little about how these two very different treatments work together. A deeper understanding about mechanisms underlying the health benefits of adding exercise to a weight loss program will not only aid efforts to optimize more effective lifestyle interventions, but it can also uncover novel targets for the treatment\u002Fprevention of obesity-related diseases.\n\nAlthough a reduction in body fat is the fundamental adaptation to weight loss, we know almost nothing about the effects that adding exercise has on structural and functional changes within fat tissue that may further enhance metabolic health. This is very important because many obesity-related metabolic health complications are tightly linked with abnormalities in abdominal fat tissue. We argue exercise-induced modifications in abdominal fat tissue will reveal persistent health benefits even if some weight is regained\n\nStudy Summary:\n\n10% Weight Loss Phase - Subject participation in the study will involve a series of metabolic tests before, at midpoint, and after undergoing a 10% weight loss program (with or without exercise training depending on group randomization). During this, subjects will be randomized into one of two different experimental groups:\n\n1. Moderate Intensity Continuous Training (MICT) exercise group\n2. No exercise (control) group\n\nFollow-up Phase: After completing the metabolic testing post-weight loss, all study-related diet and exercise supervision will end and subjects will be free to make their own choices regarding diet and exercise\u002Fphysical activity behavior. Subjects will then be asked to complete follow-up testing at 2-, 4- and 6- months post-weight loss.\n\nTotal involvement in the study for each subject will likely be about 10-13 months (4-7 months during weight loss phase, 6 months during follow-up phase).",[97,179,266,177,176,26],{"date":249,"type":34},{"date":687,"type":34},"2023-07-19",{"date":689,"type":20},"2028-05-31",{"name":276,"class":41},""]